Serplulimab
Non-clear Renal Cell Carcinoma
RenJi Hospitalmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Non-clear Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Toripalimab The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 | CCC |
Fruquintinib RenJi Hospital | Phase 2 | CCC |
Axitinib The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 | CCC |
Same molecule, other indications
Serplulimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →